Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 14/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4833314 | 0.99 | CCR2 (0.46) | CCR2CCR5KMT2ANPC1LMNA | |
| SCHEMBL4828197 | 0.92 | UTS2R (0.47) | CCR2CCR5KMT2ANPC1LMNA | |
| SCHEMBL4828074 | 0.92 | CCR2 (0.46) | CCR2CCR5KMT2ANPC1LMNA | |
| SCHEMBL14197261 | 0.92 | CCR2 (0.46) | CCR2CCR5KMT2ANPC1LMNA | |
| SCHEMBL4831015 | 0.92 | CCR2 (0.46) | CCR2CCR5KMT2ANPC1LMNA | |
| SCHEMBL4828149 | 0.92 | CCR2 (0.48) | CCR2CCR5 | |
| SCHEMBL4837067 | 0.91 | CCR2 (0.45) | CCR2CCR5KMT2A | |
| Hydrochloric Acid SCHEMBL4836333 | 0.91 | CCR2 (0.45) | CCR2CCR5KMT2ANPC1LMNA | |
| Hydrochloric Acid SCHEMBL4833819 | 0.91 | CCR2 (0.47) | CCR2CCR5 | |
| SCHEMBL4830847 | 0.91 | CCR2 (0.45) | CCR2CCR5KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351713-B2 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIRO CHEM PHARMA, INC. (CA) | 2008-04-01 | — | — | US | claimed |
| US-20050075360-A1 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIRO CHEM PHARMA, INC. (CA) | 2005-04-07 | — | — | US | claimed |
| US-7351713-B2 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIRO CHEM PHARMA, INC. (CA) | 2008-04-01 | — | — | US | disclosed |
| US-7351713-B2 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIRO CHEM PHARMA, INC. (CA) | 2008-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075360-A1 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | CCR2 6/4885CCR5 5/4885KMT2A 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.